||CsnPharm

CAS No.: 834153-87-6

(R)-Elagolix Catalog No. CSN18452

Synonyms: NBI-56418;NBI56418 Na;ABT-620

Elagolix is a highly potent, selective, orally-active, short-duration, non-peptide antagonist of the gonadotropin-releasing hormone receptor (GnRHR) (KD = 54 pM).

规格	价格	促销价格	库存	数量

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

加入购物车大规格询价

加入收藏

产品咨询

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

纯度 & 质量文件批次:

靶点选择性

生物活性

实验方案

技术信息

生物活性

描述Elagolix is a highly potent, selective, orally-active, short-duration, non-peptide antagonist of the gonadotropin-releasing hormone receptor (GnRHR) (KD = 54 pM).
临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT01817530	Heavy Uterine Bleeding ... more >> Uterine Fibroids Collapse <<	Phase 2	Completed	-	-
NCT00797225	Endometriosis	Phase 2	Completed	-	-
NCT00973973	Endometriosis, Pain	Phase 2	Completed	-	-

更多
参考文献

[1] Ezzati M, Carr BR. Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain. Womens Health (Lond). 2015 Jan;11(1):19-28.
[2] Carr B, Dmowski WP, et al. Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density. Reprod Sci. 2014 Nov;21(11):1341-51.

实验方案

计算器摩尔计算器总药量计算器工作液计算器
储存液制备
- 1 mg
- 5 mg
- 10 mg
- 1 mM
- 1.5833 mL
- 7.9165 mL
- 15.8331 mL
- 5 mM
- 0.3167 mL
- 1.5833 mL
- 3.1666 mL
- 10 mM
- 0.1583 mL
- 0.7917 mL
- 1.5833 mL

技术信息

CAS号	834153-87-6	储存条件	粉末 2-8°C 液体 -20°C:3-6 月 -80°C:12月
分子式	C32H30F5N3O5	运输	蓝冰
分子量	631.59	别名	NBI-56418;NBI56418 Na;ABT-620;Elagolix. Orilissa

大规格询价

号为必填项

姓名: 邮箱: 手机号:

留言:

提交

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT01817530	Heavy Uterine Bleeding ... more >> Uterine Fibroids Collapse <<	Phase 2	Completed	-	-
NCT00797225	Endometriosis	Phase 2	Completed	-	-
NCT00973973	Endometriosis, Pain	Phase 2	Completed	-	-
NCT00619866	Endometriosis, Pain	Phase 2	Completed	-	-
NCT01441635	Heavy Uterine Bleeding ... more >> Uterine Fibroids Collapse <<	Phase 2	Completed	-	-
NCT01403038	Folliculogenesis	Phase 1	Completed	-	United States, Colorado ... more >> Site Reference ID/Investigator# 50805 Colorado Springs, Colorado, United States, 80910 Site Reference ID/Investigator# 51270 Colorado Springs, Colorado, United States, 80917 Site Reference ID/Investigator# 50884 Denver, Colorado, United States, 80246 Site Reference ID/Investigator# 50404 Lonetree, Colorado, United States, 80124 United States, Florida Site Reference ID/Investigator# 50904 Miami, Florida, United States, 33126 Site Reference ID/Investigator# 50402 South Miami, Florida, United States, 33143 Site Reference ID/Investigator# 50808 Tampa, Florida, United States, 33606 United States, Illinois Site Reference ID/Investigator# 50807 Naperville, Illinois, United States, 60540 Site Reference ID/Investigator# 50804 Oak Brook, Illinois, United States, 60523 United States, North Carolina Site Reference ID/Investigator# 50762 Durham, North Carolina, United States, 27713 Site Reference ID/Investigator# 50403 Winston-Salem, North Carolina, United States, 27103 United States, Ohio Site Reference ID/Investigator# 50810 Cincinnati, Ohio, United States, 45267-0457 United States, Oregon Site Reference ID/Investigator# 50883 Portland, Oregon, United States, 97239 United States, Pennsylvania Site Reference ID/Investigator# 50803 Philadelphia, Pennsylvania, United States, 19104 Site Reference ID/Investigator# 51546 Philadelphia, Pennsylvania, United States, 19114 United States, Texas Site Reference ID/Investigator# 50806 San Antonio, Texas, United States, 78229 Site Reference ID/Investigator# 51342 San Antonio, Texas, United States, 78229 United States, Utah Site Reference ID/Investigator# 50811 Sandy, Utah, United States, 84070 United States, Virginia Site Reference ID/Investigator# 50902 Norfolk, Virginia, United States, 23507 United States, Washington Site Reference ID/Investigator# 50882 Seattle, Washington, United States, 98105 Puerto Rico Site Reference ID/Investigator# 53363 San Juan, Puerto Rico, 00935 Site Reference ID/Investigator# 53362 Santurce, Puerto Rico, 00910 Collapse <<
NCT00437658	-	-	Completed	-	-
NCT00973973	-	-	Completed	-	-
NCT03343067	Endometriosis	Phase 3	Terminated(Strategic considera... more >>tions) Collapse <<	-	-
NCT00619866	-	-	Completed	-	-
NCT02654054	Uterine Fibroids ... more >> Heavy Menstrual Bleeding Collapse <<	Phase 3	Active, not recruiting	December 19, 2018	-
NCT00437658	Endometriosis	Phase 2	Completed	-	-
NCT01931670	Endometriosis	Phase 3	Completed	-	-
NCT02691494	Uterine Fibroids ... more >> Heavy Menstrual Bleeding Collapse <<	Phase 3	Active, not recruiting	January 16, 2019	-
NCT00797225	-	-	Completed	-	-
NCT01620528	Endometriosis	Phase 3	Completed	-	-
NCT01931670	-	-	Completed	-	-
NCT01620528	-	-	Completed	-	-
NCT03271489	Heavy Menstrual Bleeding ... more >> Uterine Fibroids Collapse <<	Phase 3	Recruiting	May 16, 2022	-
NCT02143713	Endometriosis	Phase 3	Completed	-	-
NCT03213457	Endometriosis	Phase 3	Recruiting	December 31, 2020	-
NCT02925494	Uterine Fibroids ... more >> Heavy Menstrual Bleeding Collapse <<	Phase 3	Active, not recruiting	April 8, 2019	-
NCT01760954	-	-	Completed	-	-
NCT01760954	Endometriosis	Phase 3	Completed	-	-
NCT02143713	-	-	Completed	-	-

(R)-Elagolix Catalog No. CSN18452

靶点选择性

请登录您的专属账户

确认信息